Is TG Therapeutics, Inc. overvalued or undervalued?

As of 30 June 2025, the valuation grade for TG Therapeutics, Inc. moved from fair to very expensive, indicating a significant shift in its market perception. The company is currently overvalued, as evidenced by its high P/E ratio of 158, a Price to Book Value of 26.81, and an EV to EBITDA of 105.38, all of which are substantially higher than its peers. For instance, Catalyst Pharmaceuticals, Inc. has a P/E of 12.14 and an EV to EBITDA of 6.42, highlighting the stark contrast in valuation metrics.
In terms of performance, TG Therapeutics has shown impressive returns, with a 3-year return of 380.27%, significantly outperforming the S&P 500's 70.41% over the same period. However, despite these strong returns, the company's current valuation metrics suggest that it is priced excessively high relative to its earnings and industry peers.